Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
1. A method of treating a cerebral aneurysm in a mammal, comprising:
administering to the mammal a therapeutically effective amount of a pharmaceutical formulation comprising a compound, wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the pharmaceutical formulation is administered orally.
3. The method of claim 2 , wherein the pharmaceutical formulation is in the form of a tablet or a capsule.
4. The method of claim 3 , wherein the method further comprises administering to the mammal a therapeutically effective amount of at least a second rho kinase inhibitor.
5. The method of claim 4 , wherein the at least a second rho kinase inhibitor is
C3 protein,
netarsudil, latanoprost, Fasudil, edaravone, Azaindole 1,
Thiazovivin, Chroman 1,
Hydroxyfasudil, Ripasudil, or a pharmaceutically acceptable salt thereof, or a mixture thereof.
6. The method of claim 1 , wherein the pharmaceutical formulation further comprises a second rho kinase inhibitor.
7. The method of claim 6 , wherein the second rho kinase inhibitor is
C3 protein,
netarsudil, latanoprost, Fasudil, edaravone, Azaindole 1,
Thiazovivin, Chroman 1,
Hydroxyfasudil, Ripasudil, or a pharmaceutically acceptable salt thereof, or a mixture thereof.
8. A method of treating a cerebral aneurysm in a mammal, comprising:
administering to the mammal a therapeutically effective amount of a pharmaceutical formulation comprising a compound of the following structure:
or (R)-enantiomer thereof, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the pharmaceutical formulation is administered orally.
10. The method of claim 9 , wherein the pharmaceutical formulation is in the form of a tablet or a capsule.
11. The method of claim 10 , wherein the method further comprises administering to the mammal a therapeutically effective amount of at least a second rho kinase inhibitor.
12. The method of claim 11 , wherein the at least a second rho kinase inhibitor is
C3 protein,
netarsudil, latanoprost, Fasudil, edaravone, Azaindole 1,
Thiazovivin, Chroman 1,
Hydroxyfasudil, Ripasudil, or a pharmaceutically acceptable salt thereof, or a mixture thereof.
13. The method of claim 8 , wherein the pharmaceutical formulation further comprises a second rho kinase inhibitor.
14. The method of claim 13 , wherein the second rho kinase inhibitor is
C3 protein,
netarsudil, latanoprost, Fasudil, edaravone, Azaindole 1,
Thiazovivin, Chroman 1,
Hydroxyfasudil, Ripasudil, or a pharmaceutically acceptable salt thereof, or a mixture thereof.